Corundum Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.02M | Buy |
1,681
+10
| +0.6% | +$10.2K | 0.6% | 38 |
|
|
2026
Q1 | $1.54M | Buy |
1,671
+159
| +11% | +$161K | 0.51% | 41 |
|
|
2025
Q4 | $1.62M | Sell |
1,512
-101
| -6% | -$96.6K | 0.55% | 36 |
|
|
2025
Q3 | $1.23M | Sell |
1,613
-16
| -1% | -$11.9K | 0.51% | 47 |
|
|
2025
Q2 | $1.27M | Buy |
1,629
+584
| +56% | +$454K | 0.56% | 43 |
|
|
2025
Q1 | $863K | Sell |
1,045
-1,673
| -62% | -$1.39M | 0.41% | 58 |
|
|
2024
Q4 | $2.1M | Buy |
2,718
+1,656
| +156% | +$1.37M | 0.78% | 31 |
|
|
2024
Q3 | $941K | Sell |
1,062
-2,867
| -73% | -$2.58M | 0.43% | 55 |
|
|
2024
Q2 | $3.56M | Buy |
3,929
+2,427
| +162% | +$1.94M | 1.39% | 18 |
|
|
2024
Q1 | $1.17M | Sell |
1,502
-64
| -4% | -$45.5K | 0.56% | 40 |
|
|
2023
Q4 | $913K | Buy |
1,566
+8
| +0.5% | +$4.67K | 0.46% | 50 |
|
|
2023
Q3 | $837K | Sell |
1,558
-462
| -23% | -$238K | 0.48% | 48 |
|
|
2023
Q2 | $947K | Sell |
2,020
-2,474
| -55% | -$1.04M | 0.47% | 54 |
|
|
2023
Q1 | $1.54M | Buy |
4,494
+2,320
| +107% | +$782K | 0.73% | 42 |
|
|
2022
Q4 | $795K | Buy |
2,174
+49
| +2% | +$17.4K | 0.45% | 58 |
|
|
2022
Q3 | $687K | Buy |
2,125
+88
| +4% | +$27.9K | 0.43% | 60 |
|
|
2022
Q2 | $660K | Buy |
2,037
+59
| +3% | +$17.7K | 0.45% | 58 |
|
|
2022
Q1 | $566K | Buy |
1,978
+153
| +8% | +$39.4K | 0.53% | 71 |
|
|
2021
Q4 | $504K | Buy |
1,825
+80
| +5% | +$20.3K | 0.33% | 58 |
|
|
2021
Q3 | $403K | Buy |
1,745
+114
| +7% | +$28.1K | 0.3% | 58 |
|
|
2021
Q2 | $374K | Sell |
1,631
-151
| -8% | -$30.3K | 0.25% | 61 |
|
|
2021
Q1 | $333K | Buy |
1,782
+16
| +0.9% | +$3.13K | 0.26% | 63 |
|
|
2020
Q4 | $298K | Buy |
1,766
+140
| +9% | +$20.9K | 0.25% | 66 |
|
|
2020
Q3 | $241K | Buy |
1,626
+59
| +4% | +$9.13K | 0.23% | 67 |
|
|
2020
Q2 | $257K | Sell |
1,567
-215
| -12% | -$33K | 0.31% | 41 |
|
|
2020
Q1 | $247K | Sell |
1,782
-139
| -7% | -$19.1K | 0.35% | 40 |
|
|
2019
Q4 | $252K | Buy |
1,921
+87
| +5% | +$10.1K | 0.26% | 59 |
|
|
2019
Q3 | $205K | Sell |
1,834
-2
| -0.1% | -$223 | 0.24% | 61 |
|
|
2019
Q2 | $203K | Buy |
1,836
+14
| +0.8% | +$1.65K | 0.23% | 65 |
|
|
2019
Q1 | $236K | Sell |
1,822
-4,154
| -70% | -$505K | 0.27% | 51 |
|
|
2018
Q4 | $692K | Buy |
+5,976
| New | +$668K | 0.64% | 28 |
|
Other funds holding LLY
Corundum Group's LLY Position: Q2 2026 in Review
Corundum Group increased its Eli Lilly (LLY) stake by 0.6% in Q2 2026, buying an estimated $10.2K and bringing the position to 1,681 shares worth $2.02M. The position accounts for 0.6% of the portfolio, ranked #38.
Corundum Group first reported a position in LLY in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.56M in Q2 2024. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Corundum Group held 1,681 shares of Eli Lilly worth $2.02M as of Q2 2026.
- Corundum Group bought 10 Eli Lilly shares in Q2 2026, an estimated $10.2K.
- Eli Lilly made up 0.6% of Corundum Group's portfolio in Q2 2026, its #38 holding.
- Corundum Group first reported a position in Eli Lilly in Q4 2018 and has held it in 31 quarters since.
- Corundum Group's Eli Lilly position peaked at $3.56M in Q2 2024.
- 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Corundum Group's 13F filing for Q2 2026, filed 7 Aug 2026.